Word: alnylam
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...obstacles still lie ahead for RNAi-based drugs, not least of which is how to best deliver them to patients. To solve that question, Roche turned to the outside. Last year Roche bought a 5% stake in Alnylam, a biotech start-up based in Cambridge, Mass., that's a leader in understanding RNAi...
...When the Alnylam deal was announced in July 2007, Schwan quipped that it could become Roche's "second Genentech." In his wildest dreams. With a market cap of $95 billion, Genentech--of which Roche has owned a 55% majority stake since 1990--has produced some of the most cutting-edge best sellers on the pharmaceutical market today. Its pipeline remains one of the industry's most promising. In the past, Roche always applied a light touch to this golden goose, but this summer it became too tempting for Schwan. On July 21, in what will probably amount to a hostile...
...forecaster EvaluatePharma says Roche is on track to take over as Big Pharma's top dog by 2014, up from No. 5 today. But it won't get there without a fight. Crosstown rival Novartis is also revamping how it does R&D and holds a 13% stake in Alnylam. U.K. concern GlaxoSmithKline already underwent its own re-engineering, and the results are evident. In 2000 its pipeline had two major prospects; now, stocked with 34 late-phase drugs on the horizon, it appears to be one of the industry's healthiest...
| 1 |